Blood Cancer United Inc logo

Blood Cancer United Inc

Foundation · Grantmaker WASHINGTON, DC EIN: 13-5644916 Website

The Leukemia & Lymphoma Society (now operating as Blood Cancer United) is a 501(c)(3) nonprofit organization headquartered in Washington, DC, with additional offices in Rye Brook, New York. Founded in 1949, the organization is the largest nonprofit funder of blood cancer research globally. The organization employs 1,228 staff members and operates in the United States, Canada, and nine additional countries including the United Kingdom, Argentina, Puerto Rico, and Brazil.

Key facts about Blood Cancer United Inc

EIN
13-5644916
Latest 990 filing
Form 990-PF, 2025
Annual giving (2025)
$47,747,287
Grants made (2025)
67
Average grant
$712,646
Median grant
$370,000
Total assets
$532,209,663
Primary geography
Massachusetts (17% of itemized 2025 grant dollars)

Data from IRS Form 990-PF, 2025; updated September 2026.

Who Blood Cancer United Inc funds

By grant dollars, the top recipient states for Blood Cancer United Inc's 67 itemized 2025 grants were Massachusetts (17%), New York (16%) and California (9%). The most frequent recipient cities were Boston, MA (5 grants), New York, NY (5 grants), Philadelphia, PA (5 grants) and Atlanta, GA (3 grants). None of its 67 grants with a stated purpose were described as general or operating support. Recurring purposes include "Research Grant" (65 grants).

Financial Overview

From 2025 IRS Form 990-PF · View filing

Total Assets

$532.2M

-11.6% YoY

Annual Giving

$47.7M

-8.6% YoY

Grant Count

67

-2.9% YoY

Avg Grant Size

$713K

-5.9% YoY

Research compiled by Grantable AI from public sources. Last updated April 2026.

Mission & Focus Areas

Mission Statement: Cure blood cancer and improve the quality of life of all patients and their families.

The organization operates across three primary strategic areas:

Research Programs: The organization funds groundbreaking blood cancer research across the entire research continuum, from basic laboratory science through clinical trials to private-sector drug development partnerships. The organization has invested over $1.8 billion in research to date and has been instrumental in advancing 75% of nearly 100 new blood cancer treatment approvals over the past five years. Current research priorities include precision medicine, immunotherapy, and investigation of links between mutations and blood cancer. The organization has supported notable advances including Chimeric Antigen Receptor T cell (CAR T) therapy, which has produced cures for some patients who have exhausted other treatment options.

Policy & Advocacy: The organization's Policy & Advocacy team works to remove barriers to care through grassroots mobilization and advocacy to influence state and federal laws and regulations. The team focuses on ensuring all blood cancer patients have access to needed treatments and care.

Patient Support & Services: The organization provides disease information, treatment resources, support services, and educational resources for patients and families affected by blood cancer.

Grantmaking

The organization has committed significant funding to research initiatives:

Your AI grants department

Ready to take the next step with Blood Cancer United Inc?

Fully replaces Grant database subscriptions Instrumentl · Foundation Directory · GrantStation & similar

Geographic Focus

Where this funder awards grants

The organization funds research and provides services in the United States and internationally, including Canada, the United Kingdom, Argentina, Puerto Rico, Brazil, and nine additional countries.

Grant Distribution by State

28states

Share of all 67 itemized 2025 grant dollars.

Cities

BostonNew YorkPhiladelphiaAtlantaDallasHoustonColumbusSeattleCharlotteChicagoLos AngelesMilwaukeeMinneapolisPittsburghPortlandBronxCincinattiDuarteSt LouisAurora

Financial History

Multi-year comparison from IRS filings

Fiscal Year 2024:

  • Total Revenue: $368,242,059
  • Total Expenses: $371,792,172
  • Total Assets: $602,010,519
  • Total Liabilities: $211,000,000

Tax Status: Tax-exempt since January 2001 (EIN: 13-5644916)

Organizational Rating: The organization holds a Four-Star rating from independent charity evaluators, with a 99% overall score based on Impact & Measurement (47%), Accountability & Finance (38%), Leadership & Adaptability (10%), and Culture & Community (5%).

Revenue
Expenses
Qualifying Distributions
Net Investment Income
$0$143M$285M$428M$570M2019202020212022202320242025
Metric202520242023
Total Assets$532,209,663$602,010,519$643,891,871
Revenue$358,698,504$368,242,059$378,338,490
Expenses$398,128,476$371,792,172$386,072,968
Qualifying Distributions———
Net Investment Income$22,273,771$16,623,882$15,134,480
Distributable Amount———

Giving Over Time

Total grant dollars and number of grants per year

$0$13M$26M$39M$52M0 grants20190 grants20200 grants20210 grants202276 grants202369 grants202467 grants2025

Grant Insights

How this funder distributes its grants

Top Recipients

Top 10 recipients in 2025

Dana-farber Cancer Insti…$5.2MThe University of Texas …$2.5MSloan Kettering Institut…$2.5MThe Board of Trustees of…$2.3MWashington University in…$2.3MJoan & Sanford I Weill M…$2.1MUniversity of Florida$2.0MUniversity of Colorado D…$2.0MEmory University$1.7MFred Hutchinson Cancer C…$1.6M

Grant Size Distribution

212 grants across all recorded years

4<$50K18$50–100K61$100–250K43$250–500K39$500K–1M45$1–5M2$5M+

Open Grants

6 open opportunities from Blood Cancer United Inc

Show all 6 →

Giving History

Grant recipients and amounts by year

Among its reported 2025 grants, the largest recipients include Dana-farber Cancer Institute Inc ($5,197,687), The University of Texas Md Anderson Cancer Center ($2,518,448), Sloan Kettering Institute for Cancer Research ($2,513,800).

RecipientPurposeAmount
DANA-FARBER CANCER INSTITUTE INC BOSTON, MARESEARCH GRANT$5,197,687
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON, TXRESEARCH GRANT$2,518,448
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH NEW YORK, NYRESEARCH GRANT$2,513,800
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY STANFORD, CARESEARCH GRANT$2,257,440
WASHINGTON UNIVERSITY IN ST LOUIS ST LOUIS, MORESEARCH GRANT$2,252,023
JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY NEW YORK, NYRESEARCH GRANT$2,115,000
UNIVERSITY OF FLORIDA GAINESVILLE, FLRESEARCH GRANT$2,009,874
UNIVERSITY OF COLORADO DENVER ANSCHUTZ MEDICAL CAMPUS AURORA, CORESEARCH GRANT$1,966,500
EMORY UNIVERSITY ATLANTA, GARESEARCH GRANT$1,661,071
FRED HUTCHINSON CANCER CENTER SEATTLE, WARESEARCH GRANT$1,550,000

Leadership & Key People

Leadership team and compensation from IRS filings

E. Anders Kolb, M.D. - President & CEO

Louis J. DeGennaro - President and CEO (referenced in organizational materials regarding the Four-Star rating achievement)

Compensation Overview

From 2025 IRS filing

E ANDERS KOLBPRESIDENT & CEO$880KGWEN NICHOLSEVP, CHIEF MED OFFICER$736KGORDON MILLEREVP, CHIEF FIN OFFICER$648KDALE NISSENBAUMFORMER EVP, GEN CNSL - END 0…$548KFLORA COKER POWELLEVP, CHIEF REV OFFICER$513KSUSAN BROWNSVP, CHIEF SUS OFF END - 11/…$422KLEE GREENBERGERSVP, CHIEF SCI OFFICER - END…$409KFLORENCE GODFREYSVP, CHIEF EXPERIENCE OFFICER$406KANDREW PERRYSVP, BUS OPS AND TECHNOLOGY$392KELISA WEISSSVP, EDUCATION$368KMEREDITH FOGELEVP, GEN COUNSEL - START 09/…$312KTROY DUNMIREFORMER EVP, CF OP OFF - END …$263KSHONETTE HARRISON CA…EVP, CHIEF ADMIN OFF - START…$162KORLANDO ASHWORTHEVP, CHIEF PEOPLE - START 10…$95K

From 2025 filing

NameTitleHoursCompensation
ALESSANDRA TOCCOCHAIR4—
FREDA WANGVICE CHAIR4—
MARLA PERSKYSECRETARY/TREASURER4—
JANICE GABRILOVE MDAT LARGE4—
LEROY BALLBOD MEMBER4—
RICHARD BAGGERBOD MEMBER4—
MARK BARRENECHEABOD MEMBER4—
RENZO CANETTABOD MEMBER4—
M CASEY CUNNINGHAMBOD MEMBER4—
SHARON CASTELLINOBOD MEMBER4—
MIKE FARMERBOD MEMBER4—
ARI MELNICKBOD MEMBER4—
KATHLEEN MERIWETHERBOD MEMBER4—
RUBEN MESABOD MEMBER4—
LYNNE O'BRIENBOD MEMBER4—
ALEX OKAFORBOD MEMBER4—
JIM REDDOCHBOD MEMBER4—
RICHARD RENDINABOD MEMBER4—
ROBERT ROSENBOD MEMBER4—
RAYNE H ROUCE MDBOD MEMBER4—
JEFF SACHSBOD MEMBER4—
LILIAN STERNBOD MEMBER4—
YVETTE TREMONTIBOD MEMBER4—
E ANDERS KOLBPRESIDENT & CEO40$879,998
GWEN NICHOLSEVP, CHIEF MED OFFICER40$736,394
GORDON MILLEREVP, CHIEF FIN OFFICER40$648,480
FLORA COKER POWELLEVP, CHIEF REV OFFICER40$512,813
MEREDITH FOGELEVP, GEN COUNSEL - START 09/202440$312,368
SHONETTE HARRISON CAREWEVP, CHIEF ADMIN OFF - START 09/202440$162,265
ORLANDO ASHWORTHEVP, CHIEF PEOPLE - START 10/202440$95,040
LEE GREENBERGERSVP, CHIEF SCI OFFICER - END 12/202440$408,560
SUSAN BROWNSVP, CHIEF SUS OFF END - 11/12/202440$421,797
FLORENCE GODFREYSVP, CHIEF EXPERIENCE OFFICER40$406,318
ELISA WEISSSVP, EDUCATION40$367,828
ANDREW PERRYSVP, BUS OPS AND TECHNOLOGY40$391,677
DALE NISSENBAUMFORMER EVP, GEN CNSL - END 05/202440$547,759
TROY DUNMIREFORMER EVP, CF OP OFF - END 01/202440$263,181

Recent News & Activity

Recent developments and announcements

The organization has announced multiple significant research funding commitments and partnerships:

Awarded $65 million in new funding for blood cancer research

The Leukemia & Lymphoma Society Awards $65 Million in New Funding for Blood

Committed $188 million to fuel next generation of cancer research

LLS Fuels Next Generation of Cancer Research Committing $188 Million

Partnered with Blood Cancer UK to award $4.25 million for research into prevention of leukemia

The Leukemia & Lymphoma Society Awards $65 Million in New Funding for Blood

Invested $6.5 million in research investigating causes of inequitable access to blood cancer treatment and care

The Leukemia & Lymphoma Society Awards $65 Million in New Funding for Blood

Funded immunotherapy studies demonstrating remarkable results in patients with acute lymphoblastic leukemia

Immunotherapy Study Funded by The Leukemia & Lymphoma Society Demonstrates

The organization maintains active engagement in policy advocacy and continues to expand research initiatives focused on precision medicine, immunotherapy, and addressing health disparities in blood cancer treatment and clinical trial participation.

LLS Fuels Next Generation of Cancer Research Committing $188 Million

Subject Areas

Focus areas based on grantmaking activity

Frequently Asked Questions

What does Blood Cancer United Inc fund?

**Mission Statement:** Cure blood cancer and improve the quality of life of all patients and their families. The organization operates across three primary strategic areas: **Research Programs:** The organization funds groundbreaking blood cancer research across the entire research continuum, from basic laboratory science through clinical trials to private-sector drug development partnerships. The organization has invested over $1.8 billion in research to date and has been instrumental in advan…

How do I apply for a grant from Blood Cancer United Inc?

The organization has committed significant funding to research initiatives: • **$65 million** in new funding for blood cancer research (recent announcement) • **$188 million** commitment to fuel next generation of cancer research • **$54.6 million** in total research disbursement in fiscal year 2022, supporting research in the US, Canada, and nine other countries • **$6.5 million** invested in research investigating causes of inequitable access to blood cancer treatment and care • **$4.25 milli…

Where does Blood Cancer United Inc make grants?

The organization funds research and provides services in the United States and internationally, including Canada, the United Kingdom, Argentina, Puerto Rico, Brazil, and nine additional countries.

What size grants does Blood Cancer United Inc award?

In 2025, Blood Cancer United Inc awarded 67 grants totaling $47.7M — an average of about $713K per grant, based on its IRS Form 990 filings.

What is Blood Cancer United Inc's EIN?

Blood Cancer United Inc's EIN (Employer Identification Number) is 13-5644916. IRS Form 990 filing data is available on this page for 2019–2025.

Explore Open Grants

Browse active grant opportunities in Blood Cancer United Inc's focus areas in our free grants database

Similar Funders

Funders that support many of the same organizations

More Funders in District of Columbia

Data last updated September 2026. Sourced from IRS Form 990-PF filings. Research dossier generated April 2026.

Your AI grants department

Here's the math on researching Blood Cancer United Inc by hand.